|
|||||
|
|
| 重组链激酶、尿激酶溶栓治疗急性心肌梗死的对比研究 | |
| 引用本文： | 张丽贞,张秀兰,陈洁,孔梅. 重组链激酶、尿激酶溶栓治疗急性心肌梗死的对比研究[J]. 中西医结合心脑血管病杂志, 2005, 3(4): 297-298 |
| 作者姓名： | 张丽贞 张秀兰 陈洁 孔梅 |
| 作者单位： | 1. 山西省心血管疾病医院,030024 2. 山西医科大学第二医院 3. 山西省心血管疾病医院 |
| 摘 要： | 目的观察国产重组链激酶(r-SK)在急性心肌梗死(AMI)静脉溶栓治疗中的临床疗效和不良反应,用尿激酶(UK)作为对照,评价r-SK的安全性.方法采用平行随机单盲对照试验,将128例符合入选标准的AMI病人随机分为两组,r-SK组65例,UK组63例,予r-SK 1.5×106 U于60 min内静脉输注,UK 1.5×106 U于30 min内静脉输注,观察血管再通的临床指标、药物不良反应及出血并发症等.结果在随机单盲对照试验中,r-SK组的血管再通率为81.5%,UK组的血管再通率为58.7%,两组相比有统计学意义(P＜0.05),r-SK 组的不良反应中,变态反应(寒战、发热及皮疹等)的发生率为9.5%,UK组为11.3%(P＞0.05),低血压的发生率两组相比无统计学意义,两组均无过敏性休克和颅内出血发生.结论国产r-SK是一种血管再通率较高,不良反应及出血并发症发生率低,安全有效的溶栓药物. |
| 关 键 词： | 重组链激酶 尿激酶 急性心肌梗死 溶栓治疗 |
| 文章编号： | 1672-1349(2005)04-0297-02 |
| 修稿时间： | 2004-04-12 |
Comparison of Therapy with Recombinant Streptokinase(r-SK)and Urokinase for Acute Myocardial infarction |
|
| Zhang Lizhen,Zhang Xiulan,Chen jie,et al Shanxi Cardiovascular Hospital. Comparison of Therapy with Recombinant Streptokinase(r-SK)and Urokinase for Acute Myocardial infarction[J]. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, 2005, 3(4): 297-298 | |
| Authors: | Zhang Lizhen Zhang Xiulan Chen jie et al Shanxi Cardiovascular Hospital |
| Affiliation: | Taiyuan 030024 |
| Abstract: | Objective To evaluate the efficacy and safety of intravenous recombinant streptokinase (r-SK),produced in China,compared with urokinase (UK) in the treatment of acute myocardial infarction (AMI).Methods 128 patients with AMI were randomly assigored to receive r-sk(n=65)or UK(n=63).Revas cullarization index adverse effects and hemorrhase were assessed.Result The revascularization rate for r-SK was 81.5%,and 58.7% for UK B(P<0.05).Rigor,hypotension and mild bleeding were not significant between two groups. Conclusion China-made r-SK is a safe and effective thrombolytic agent. |
| Keywords: | recombinant streptokinase urokinase acute myocardial infarction thrombolytic therapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |